Last reviewed · How we verify
syntocinon nasal spray
Syntocinon (oxytocin) nasal spray binds to oxytocin receptors to stimulate uterine contractions and promote milk letdown during lactation.
Syntocinon (oxytocin) nasal spray binds to oxytocin receptors to stimulate uterine contractions and promote milk letdown during lactation. Used for Labor induction and augmentation, Prevention and treatment of postpartum hemorrhage, Promotion of milk letdown during breastfeeding.
At a glance
| Generic name | syntocinon nasal spray |
|---|---|
| Also known as | nasal oxytocin - 24 IU, |
| Sponsor | Rambam Health Care Campus |
| Drug class | Oxytocin receptor agonist |
| Target | Oxytocin receptor (OXTR) |
| Modality | Small molecule |
| Therapeutic area | Obstetrics and Gynecology |
| Phase | FDA-approved |
Mechanism of action
Oxytocin is a neurohypophyseal hormone that acts on G-protein coupled oxytocin receptors located on uterine smooth muscle and mammary gland myoepithelial cells. In obstetrics, it induces or augments labor by triggering rhythmic uterine contractions. In lactation, it facilitates milk ejection by contracting the myoepithelial cells surrounding the alveoli.
Approved indications
- Labor induction and augmentation
- Prevention and treatment of postpartum hemorrhage
- Promotion of milk letdown during breastfeeding
Common side effects
- Uterine hyperstimulation
- Nausea
- Vomiting
- Headache
- Flushing
- Hypertension
Key clinical trials
- Evaluating the Efficacy of Intranasal Oxytocin on Chronic Pain (PHASE2, PHASE3)
- Opioid-Sparing and Pain-Reducing Properties of Syntocinon: A Dose-Effect Determination (EARLY_PHASE1)
- Oxytocin Substitution Therapy in Patients With Central Diabetes Insipidus (PHASE2)
- Oxytocin-Augmented Group Psychotherapy for Patients With Schizophrenia - an Oxytocin-dose Comparison (NA)
- OXYMIND: Oxytocin-augmented Group Psychotherapy for Patients With Schizophrenia (NA)
- A Study of the Effects of Oxytocin in Adults With Binge-eating Disorder (PHASE2)
- Intranasal Oxytocin Intervention for Caregivers to Persons With Dementia (PHASE2)
- Oxytocin and Human Defensive Responses in a Dynamic Situation (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- syntocinon nasal spray CI brief — competitive landscape report
- syntocinon nasal spray updates RSS · CI watch RSS
- Rambam Health Care Campus portfolio CI